TOMI Environmental Solutions Receives Biocidal Product Approvals in Great Britain and Northern Ireland

Rhea-AI Summary

TOMI Environmental Solutions (NASDAQ: TOMZ) received Health and Safety Executive authorizations GB-2016-1042 (Great Britain) and NI-2026-1350 (Northern Ireland) on Feb. 23, 2026, allowing its Binary Ionization Technology (BIT) and SteraMist iHP products for registered biocidal uses.

Approvals cover room fogging and handheld surface spray on dry, pre-cleaned, hard, non-porous surfaces across healthcare, industrial, hospitality, and institutional sectors; specific EN and AOAC efficacy contact times are listed for bactericidal, yeasticidal, and virucidal claims.

Positive

• Official HSE authorizations: GB-2016-1042 and NI-2026-1350
• Approved for room fogging and handheld spray surface applications
• Efficacy claims include EN 13727, EN 13624, EN 14476 with 5–15 minute contact times

Negative

• Use limited to dry, pre-cleaned, hard, non-porous, non-food contact surfaces
• EU market access remains pending—EU BPR approval is not yet granted

News Market Reaction – TOMZ

+12.70% 776.6x vol

12 alerts

+12.70% Session close to close

+17.3% Peak Tracked

-19.8% Trough Tracked

$15.98M Market Cap

776.6x Rel. Volume

In the Feb 23 session, TOMZ gained 12.70%, reflecting a significant positive market reaction. Argus tracked a peak move of +17.3% during that session. Argus tracked a trough of -19.8% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 776.6x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +12.7% in the session following this news. A strong positive reaction aligns with a...

Analysis

The stock surged +12.7% in the session following this news. A strong positive reaction aligns with a clearly value-relevant milestone: official biocidal product authorizations for BIT and SteraMist equipment in Great Britain and Northern Ireland. Recent history shows that operational wins have sometimes produced muted or even negative next-day moves, so a large gain would stand out relative to prior patterns. Investors would still need to weigh ongoing Nasdaq listing deficiencies and the unused $50,000,000 shelf capacity as potential overhangs on longer-term sustainability.

Key Figures

S-3 shelf size: $50,000,000 Equity facility size: $20,000,000 Nasdaq bid price minimum: $1.00 per share +5 more

8 metrics

S-3 shelf size $50,000,000 Maximum aggregate offering under S-3 filed Nov 14, 2025

Equity facility size $20,000,000 Equity Purchase Agreement with Hudson Global Ventures

Nasdaq bid price minimum $1.00 per share Minimum bid price requirement with grace period to May 18, 2026

Stockholders’ equity requirement $2,500,000 Nasdaq minimum stockholders’ equity threshold

Shares outstanding 20,225,205 shares Common shares outstanding as of Nov 14, 2025

Authorized common shares 250,000,000 shares Authorized common stock per S-3 summary

Insider purchase price $0.79 per share Open-market director purchases on Jan 9, 2026

Disinfection contact time 5–15 minutes BIT solution efficacy claims in GB for surface and room fogging

Historical Context

5 past events · Latest: Jan 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 20	UK CES integration	Positive	+0.6%	Sale of SteraMist CES into UK modular cleanroom platform for pharma use.
Jan 06	Hybrid system sale	Positive	-3.0%	SteraMist Hybrid System installed at research university sterilization facility.
Dec 22	Cell/gene facility win	Positive	+2.2%	Multi-stage SteraMist iHP rollout at commercial cell and gene therapy site.
Dec 18	Biopharma PO $500k	Positive	-0.1%	Approx. $500,000 SteraMist integration order from global biopharma leader.
Dec 15	Cruise line outreach	Positive	-5.1%	Call for cruise lines to adopt hospital-grade SteraMist decontamination tech.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive commercial/strategic news has produced mixed reactions, with more instances of divergence than alignment between fundamentally positive headlines and next-day price moves.

Recent Company History

Over the last few months, TOMI has reported a series of SteraMist deployments and commercial wins, including a $500,000 purchase order with a global biopharma leader on Dec 18, 2025 and multi-stage implementation at a cell and gene therapy facility on Dec 22, 2025. Additional installations at a research university and a UK CES integration further expanded use cases. Despite generally positive operational updates, 24-hour price reactions have been inconsistent, sometimes negative even on constructive news. Today’s UK and Northern Ireland biocidal approvals extend that regulatory/commercial trajectory.

Key Terms

health and safety executive, binary ionization technology, biocidal product, regulation 528/2012, +4 more

8 terms

health and safety executive regulatory

"Health and Safety Executive (HSE), Great Britian’s national regulator for health and safety"

A health and safety executive is a government agency or regulator responsible for setting and enforcing rules that keep workers and workplaces safe, investigating serious accidents, and issuing guidance or penalties when standards are not met. Think of it as a building inspector for workplace safety: its findings can lead to fines, operational changes, legal liability, or reputational damage, so investors watch such actions because they can affect a company’s costs, operations and risk profile.

binary ionization technology technical

"granted official authorization for its Binary Ionization Technology (BIT) solution"

Binary ionization technology is a method that uses controlled electrical charges to change or activate substances at a molecular level, often for purposes like sterilization or purification. For investors, it matters because innovations in this technology can lead to new products or processes that improve efficiency and safety, potentially creating new market opportunities and driving growth in related industries.

biocidal product regulatory

"The BIT Solution is now formally approved as a biocidal product for use in Great Britain"

A biocidal product is a chemical or biological substance designed to kill, deter, or control harmful organisms such as bacteria, viruses, fungi or pests — think disinfectants, insect sprays or preservatives that keep products from spoiling. Investors care because these products face strict safety testing, approvals and labeling rules that affect how quickly they can reach markets, the cost of compliance, recurring sales patterns, and potential liability or recall risk, all of which influence revenue and valuation.

regulation 528/2012 regulatory

"under Regulation 528/2012 GB. A separate approval was also received for Northern Ireland under Regulation (EU) No. 528/2012."

A European Union rule that sets safety, testing and approval requirements for biocidal products—items like disinfectants, insecticides and preservatives—to make sure they work and don’t harm people or the environment. For investors it matters because the rule controls which products can be sold, how long approvals last, and what testing or label changes companies must pay for, affecting market access, costs, supply and regulatory risk, much like a mandatory safety passport for chemical products.

ionized hydrogen peroxide medical

"produce a fog of ionized Hydrogen Peroxide (iHP™), which creates a germ-killing aerosol"

Ionized hydrogen peroxide is a form of hydrogen peroxide that has been electrically charged to create reactive particles. This process enhances its ability to kill germs and break down contaminants, making it more effective for cleaning and disinfecting. For investors, understanding its use and effectiveness can be important when evaluating companies involved in health, sanitation, or innovative cleaning technologies.

aoac germicidal spray method technical

"AOAC Germicidal Spray Method; NF-T 72-281; EN 13697 | 7 min."

AOAC germicidal spray method is an industry-standard laboratory test created by AOAC International to measure how well a disinfectant spray kills specified microbes on surfaces. Think of it as a certified checklist and stopwatch that shows whether a product lives up to its cleaning claims; for investors, passing this test affects regulatory acceptance, marketing credibility, product liability risk, and the ability to reach institutional buyers.

en 13727 technical

"EN 13727 | 5 min. | EN 13624 | 5 min. | EN 14476 | 5 min."

EN 13727 is a European laboratory standard that measures whether a disinfectant kills bacteria under controlled conditions, specifying how the test is done and what counts as a pass. Think of it as a crash-test rating for antibacterial cleaners: passing the test lets a manufacturer claim efficacy, helps win hospital or institutional contracts, and reduces regulatory or procurement hurdles—information investors use to judge product reliability and market access.

room fogging technical

"The BIT solution is approved under Regulation 528/2012 for room fogging and handheld direct spray"

Room fogging is a cleaning method that sprays a fine mist of disinfectant into an enclosed space so the droplets settle on surfaces and in hard‑to‑reach areas, similar to how a sprinkler wets an entire lawn. Investors care because it affects operating costs, regulatory compliance, guest and patient safety, and brand reputation for businesses like hotels, healthcare facilities, and property managers—factors that can influence revenue, liability, and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Health and Safety Executive (HSE) grants Authorization Nos.: GB-2016-1042 and NI-2026-1350

FREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced that Health and Safety Executive (HSE), Great Britian’s national regulator for health and safety, has granted official authorization for its Binary Ionization Technology (BIT) solution and the SteraMist iHP brand of disinfection equipment. The BIT Solution is now formally approved as a biocidal product for use in Great Britain, which includes England, Scotland, and Wales under Regulation 528/2012 GB. A separate approval was also received for Northern Ireland under Regulation (EU) No. 528/2012.

This milestone marks a significant achievement for TOMI, as it paves the way for expanding the availability of BIT and SteraMist products in both Great Britain and Northern Ireland. The BIT solution is approved under Regulation 528/2012 for room fogging and handheld direct spray applications. It is intended for use as a microbial disinfectant on surfaces, walls, floors, furniture, and rooms across various sectors, including healthcare, industrial, commercial, hospitality, and institutional settings.

Elissa J. Shane, COO of TOMI, stated, “This not only enhances our market footprint but also reinforces our commitment to providing innovative solutions that meet rigorous compliance, safety, and efficacy standards. We are optimistic that our separate application under the EU Biocidal Products Regulation (BPR) for the European Union will also be approved this year, opening doors in additional countries across Europe.”

The BIT solution is designed for disinfection of all dry, pre-cleaned, hard, non-porous, non-food contact surfaces in spaces such as pharmaceutical manufacturing clean rooms, tissue labs, laboratories, animal research facilities, hotel rooms, cruise ships, and recreational facilities.

The following efficacy claims have been established for TOMI's BIT solution in Great Britain:

STANDARD	CONTACT TIME	STANDARD	CONTACT TIME	STANDARD	CONTACT TIME
Bactericidal		Yeasticidal		Virucidal
SURFACE APPLICATION
EN 13727	5 min.	EN 13624	5 min.	EN 14476	5 min.
AOAC Germicidal Spray Method; NF-T 72-281; EN 13697	7 min.	NF T 72-281; EN 13697	7 min.	AOAC Germicidal Spray Method; NF T 72-281:	7 min.
ROOM FOGGING
EN 13727	5 min	EN 13624	5 min	EN 14476	5 min
NF T 72-281 EN 13697; AOAC Germicidal Fog Method	15 min.	NF T 72-281; EN 13697	15 min.	NF T 72-28; AOAC Germicidal Spray Method	15 min.

TOMI’s SteraMist products utilize a low percentage of Hydrogen Peroxide as the only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™), which creates a germ-killing aerosol that functions like a non-caustic gas. These products are designed for a wide range of applications, including hospitals, medical facilities, schools, restaurants, military barracks, and more.

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world^®

TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services serving the food safety sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:  

John Nesbett/Rosalyn Christian  

IMS Investor Relations  

tomi@imsinvestorrelations.com  

FAQ

What approvals did TOMI (TOMZ) receive in Great Britain and Northern Ireland on Feb. 23, 2026?

TOMI received HSE authorizations GB-2016-1042 for Great Britain and NI-2026-1350 for Northern Ireland. According to the company, these approvals register BIT and SteraMist iHP as biocidal products for specified surface and room fogging uses.

What applications are authorized for TOMI's BIT solution under the HSE approvals?

The BIT solution is authorized for room fogging and handheld direct spray on hard, non-porous surfaces. According to the company, intended sectors include healthcare, industrial, hospitality, and institutional environments.

Which efficacy standards and contact times does TOMI's BIT claim in Great Britain?

BIT lists standards such as EN 13727, EN 13624, EN 14476 with contact times from 5 to 15 minutes. According to the company, AOAC and NF-T methods are also cited for 7–15 minute validations.

Does the HSE authorization allow TOMI to sell SteraMist iHP across all surface types?

No, authorization covers dry, pre-cleaned, hard, non-porous, non-food contact surfaces only. According to the company, BIT is not approved for porous or food-contact surface disinfection under these authorizations.

What geographic expansion does the HSE approval enable for TOMI (TOMZ)?

The approvals permit commercial availability of BIT and SteraMist in Great Britain and Northern Ireland. According to the company, this paves the way to expand product distribution within those jurisdictions.

Has TOMI received EU-wide approval for BIT under the Biocidal Products Regulation (BPR)?

Not yet; the EU BPR approval is stated as pending and expected this year. According to the company, a separate EU application remains under review and could open additional European markets if approved.